Pipeline Overview

We are assembling a robust portfolio of allogeneic iPSC derived NK, γδ and αβ T cell therapy product candidates for cancer and autoimmune and inflammatory diseases. All of our product candidates incorporate our proprietary Allo-Evasion™ technology to avoid host rejection and potentially increase the durability of clinical responses. Enhancements in this platform have led to the generation of cells with pan-resistance to host T cell, NK, and antibody (ADCC/ADCP/Complement) mediated rejection to potentially optimize and increase the probability of success of our programs across hematology, oncology, and autoimmune and inflammatory diseases.